Compare IOVA & KMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | KMX |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.6B |
| IPO Year | 2008 | 2002 |
| Metric | IOVA | KMX |
|---|---|---|
| Price | $7.41 | $50.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 21 |
| Target Price | $14.50 | ★ $60.71 |
| AVG Volume (30 Days) | ★ 12.8M | 2.1M |
| Earning Date | 11-05-2026 | 12-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ 2.47 |
| Revenue | N/A | ★ $25,881,131,000.00 |
| Revenue This Year | $58.86 | $4.71 |
| Revenue Next Year | $41.86 | $3.06 |
| P/E Ratio | ★ N/A | $20.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.08 | $34.71 |
| 52 Week High | $15.37 | $65.28 |
| Indicator | IOVA | KMX |
|---|---|---|
| Relative Strength Index (RSI) | 31.10 | 40.14 |
| Support Level | $3.57 | $49.91 |
| Resistance Level | $9.36 | $54.41 |
| Average True Range (ATR) | 0.57 | 2.09 |
| MACD | -0.13 | -0.30 |
| Stochastic Oscillator | 4.34 | 6.68 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
CarMax sells, finances, and services used and new cars through a chain of over 255 retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 80% of fiscal 2026 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2026, the company retailed and wholesaled 780,684 and 538,203 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US, but still estimates that it had only about 3.6% US market share of vehicles zero to 10 years old in calendar 2025. CarMax is based in Richmond, Virginia.